DNTH MEXC RealStocks
Own real DNTH shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 05:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Dianthus Therapeutics, Inc. (DNTH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $83.93, with a market capitalization of $5.04B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $35.84 to $117.88. This page covers its latest market performance, valuation, price trends and company information.
$5.04B | |
$86.84 | |
$88.89 | |
$83.68 | |
$86.98 | |
673.57K | |
845.70K | |
-- | |
$117.88 | |
$35.84 | |
-- | |
2026-09-30 |
Dianthus Therapeutics, Inc. (DNTH) last closed at $83.93 as of 2026-11-19 00:31:00, down 3.52% ($3.06) from the previous close of $86.98.
During the latest regular trading session, DNTH traded between $83.68 and $88.89, with a volume of 673.57K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Dianthus Therapeutics, Inc. (DNTH) moved from $90.00 to $83.93, representing a decline of 6.74% ($6.07).
The stock traded between $83.68 and $93.81 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 682.42 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 58.6%
DNTH is currently trading at $83.93, placing it 58.6% of the way from its 52-week low of $35.84 to its 52-week high of $117.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Dianthus Therapeutics, Inc. (DNTH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DNTH, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DNTH shares and USD.
DNTH Shares to USD
1.00 DNTH shares = 83.93 USD
Calculations are estimates based on the latest available price and are for reference only.